(Q39568944)

13 September 2017

Regenerating islet-derived family member, 4 modulates multiple receptor tyrosine kinases and mediators of drug resistance in cancer (English)

1 reference

13 September 2017

multiple drug resistance

1 reference

Kathryn Vanderlaag

1

1 reference

13 September 2017

Wei Wang

2

1 reference

13 September 2017

Laurence Fayadat-Dilman

3

1 reference

13 September 2017

Janet Wagner

4

1 reference

13 September 2017

Laura Bald

5

1 reference

13 September 2017

Jeff Grein

6

1 reference

13 September 2017

Mary J Janatpour

7

1 reference

13 September 2017

language of work or name

English

0 references

publication date

9 June 2011

1 reference

International Journal of Cancer

13 September 2017

1 reference

13 September 2017

130

1 reference

13 September 2017

6

1 reference

13 September 2017

1251-1263

1 reference

13 September 2017

The Hallmarks of Cancer

1 reference

The protein kinase complement of the human genome

21 January 2018

1 reference

Untangling the ErbB signalling network

21 January 2018

1 reference

Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).

21 January 2018

1 reference

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling

21 January 2018

1 reference

Human RegIV protein adopts a typical C-type lectin fold but binds mannan with two calcium-independent sites

21 January 2018

1 reference

Reg gene family and human diseases

21 January 2018

1 reference

REG4 is associated with carcinogenesis in the 'intestinal' pathway of intraductal papillary mucinous neoplasms.

21 January 2018

1 reference

Reg IV expression is associated with cell growth and prognosis of adenoid cystic carcinoma in the salivary gland

21 January 2018

1 reference

Reg IV is an independent prognostic factor for relapse in patients with clinically localized prostate cancer

21 January 2018

1 reference

Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy

21 January 2018

1 reference

Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4.

21 January 2018

1 reference

Reg IV regulates normal intestinal and colorectal cancer cell susceptibility to radiation-induced apoptosis

21 January 2018

1 reference

Reg IV expression and clinicopathologic features of gallbladder carcinoma.

21 January 2018

1 reference

Reg IV: a promising marker of hormone refractory metastatic prostate cancer

21 January 2018

1 reference

The reg4 gene, amplified in the early stages of pancreatic cancer development, is a promising therapeutic target

21 January 2018

1 reference

Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer

21 January 2018

1 reference

Reg IV enhances peritoneal metastasis in gastric carcinomas

21 January 2018

1 reference

Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas

21 January 2018

1 reference

RegIV potentiates colorectal carcinoma cell migration and invasion via its CRD domain

21 January 2018

1 reference

Dysregulation of Reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes

21 January 2018

1 reference

RegIV expression showing specificity to gastrointestinal tract and its potential role in diagnosing digestive tract neuroendocrine tumor

21 January 2018

1 reference

Expression of the REG IV gene in ulcerative colitis

21 January 2018

1 reference

Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells

21 January 2018

1 reference

The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance

21 January 2018

1 reference

The EGF receptor interacts with the type 1 IGF receptor and regulates its stability

21 January 2018

1 reference

Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists

21 January 2018

1 reference

Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.

21 January 2018

1 reference

Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer

21 January 2018

1 reference

New approaches in hormone refractory prostate cancer

21 January 2018

1 reference

Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention

21 January 2018

1 reference

HSP27 and HSP70: potentially oncogenic apoptosis inhibitors

21 January 2018

1 reference

Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer

21 January 2018

1 reference

Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.26089

1 reference

release_pawa6byzc5gevifkf7fklvz34y

13 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pawa6byzc5gevifkf7fklvz34y

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference